Matthew Bowen sold $137 of GLUE
Principal Accounting Officer at Monte Rosa Therapeutics, Inc.. 13 shares at an average of $10.56, traded Oct 5, 2026, filed Oct 6, 2026.
Score components
- +15RoleOfficer
- 0Trade size$137 at market
- 0Share of holdings soldSold 0.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-415540, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOpen-market sale Common Stock | -13 | $10.56 | $137 | 25,891 | 6 d ago |
Related signals
Other insiders at Monte Rosa Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Edmund Dunn Principal Accounting Officer | $9,174 2,062 shares | -8% | |
| 37Weak | GLUEsell Monte Rosa Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $1.5M 157,895 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.